Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 2.29 is 1088% above its 5-year average of -0.23, near the high end of its 5-year range (-1.40–2.29).
110.09% above its 12-month average of 1.09.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.29.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:10:53.390Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
2.29
EARNINGS PER SHARE (EPS) AVG TTM
1.09
EARNINGS PER SHARE (EPS) AVG 3Y
0.22
EARNINGS PER SHARE (EPS) AVG 5Y
-0.23
EARNINGS PER SHARE (EPS) AVG 10Y
-0.43
EARNINGS PER SHARE (EPS) AVG 15Y
-0.74
EARNINGS PER SHARE (EPS) AVG 20Y
-0.83
CURRENT VS TTM AVG
+110.09%
CURRENT VS 3Y AVG
+940.91%
CURRENT VS 5Y AVG
+1088.49%
CURRENT VS 10Y AVG
+631.32%
CURRENT VS 15Y AVG
+408.70%
CURRENT VS 20Y AVG
+374.87%
Aurinia Pharmaceuticals Inc.
Market Cap
$2.02B
Earnings Per Share (EPS)
2.29
TTM Avg
1.09
3Y Avg
0.22
5Y Avg
-0.23
Market Cap
$2.01B
Earnings Per Share (EPS)
-4.24
TTM Avg
-2.98
3Y Avg
-3.43
5Y Avg
-3.06
Market Cap
$2.00B
Earnings Per Share (EPS)
4.62
TTM Avg
3.38
3Y Avg
1.11
5Y Avg
0.12
Market Cap
$2.06B
Earnings Per Share (EPS)
-1.50
TTM Avg
0.42
3Y Avg
-0.42
5Y Avg
-0.63
Market Cap
$2.07B
Earnings Per Share (EPS)
-0.93
TTM Avg
-7.24
3Y Avg
-4.12
5Y Avg
-3.06
Market Cap
$1.95B
Earnings Per Share (EPS)
-0.68
TTM Avg
-0.29
3Y Avg
-0.44
5Y Avg
-0.50
Market Cap
$2.09B
Earnings Per Share (EPS)
-4.36
TTM Avg
-3.17
3Y Avg
-2.92
5Y Avg
-2.56
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.02B | 2.29 | 1.09 | 0.22 | -0.23 |
| Progyny, Inc. (PGNY)vs › | $2.04B | 0.92 | 0.64 | 0.56 | 0.59 |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.01B | -4.24 | -2.98 | -3.43 | -3.06 |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.00B | 4.62 | 3.38 | 1.11 | 0.12 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.06B | -1.50 | 0.42 | -0.42 | -0.63 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.07B | -0.93 | -7.24 | -4.12 | -3.06 |
| Alvotech (ALVO)vs › | $2.07B | -0.63 | -0.39 | -1.45 | -2.42 |
| AxoGen, Inc. (AXGN)vs › | $1.95B | -0.68 | -0.29 | -0.44 | -0.50 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.09B | -4.36 | -3.17 | -2.92 | -2.56 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 5.70 | 4.76 | 4.08 | 3.55 |
Trailing EPS (TTM)
$2.29
Forward EPS (Est.)
$0.94
P/E Ratio
6.9
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 2.14 |
| 2024-12-31 | 0.04 |
| 2023-12-31 | -0.54 |
| 2022-12-31 | -0.76 |
| 2021-12-31 | -1.40 |
| 2020-12-31 | -0.87 |
| 2018-12-31 | -0.76 |
| 2017-12-31 | -0.92 |
| 2016-12-31 | -0.66 |
| 2015-12-31 | -0.58 |
| 2014-12-31 | -0.57 |
| 2013-12-31 | -0.40 |
| 2012-12-31 | -2.74 |
| 2011-12-31 | -0.70 |
| 2010-12-31 | -1.44 |
| 2009-12-31 | -3.17 |
| 2008-12-31 | -7.47 |
| 2007-12-31 | -16.34 |
| 2006-12-31 | -13.73 |
| 2005-12-31 | -18.51 |
| 2004-12-31 | -14.97 |
| 2003-12-31 | -10.41 |
| 2002-12-31 | -0.32 |
| 2001-12-31 | -7.22 |
| 2000-11-30 | -8.39 |
| 1999-11-30 | -2.25 |
| 1998-11-30 | -4.56 |
